HUP0003885A2 - Formulation for treating congestive heart failure - Google Patents
Formulation for treating congestive heart failureInfo
- Publication number
- HUP0003885A2 HUP0003885A2 HU0003885A HUP0003885A HUP0003885A2 HU P0003885 A2 HUP0003885 A2 HU P0003885A2 HU 0003885 A HU0003885 A HU 0003885A HU P0003885 A HUP0003885 A HU P0003885A HU P0003885 A2 HUP0003885 A2 HU P0003885A2
- Authority
- HU
- Hungary
- Prior art keywords
- formulation
- heart failure
- congestive heart
- treating congestive
- active ingredient
- Prior art date
Links
- 206010007559 Cardiac failure congestive Diseases 0.000 title 1
- 206010019280 Heart failures Diseases 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000000969 carrier Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgya orális vagy beültetendő, a hatóanyagot nem azonnalfelszbadító gyógyszerkészítmény, mely a monoxinidinnek vagygyógyászati szempontból alkalmazható sójának hatásos mennyiségéttartalmazza egy vagy több vivőanyag, hígító- vagy köztes anyagkíséretében, melyek biztosítják, hogy a hatóanyag nem azonnal szabadulfel a készítményből. ÓThe subject of the invention is an oral or implantable pharmaceutical preparation that does not immediately release the active ingredient, which contains an effective amount of monoxinidine or its salt that can be used from a medical point of view, accompanied by one or more carriers, diluents or intermediates, which ensure that the active ingredient is not immediately released from the preparation. HE
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65946396A | 1996-06-06 | 1996-06-06 | |
PCT/US1997/009914 WO1997046241A1 (en) | 1996-06-06 | 1997-06-05 | Formulation and method for treating congestive heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0003885A2 true HUP0003885A2 (en) | 2001-04-28 |
Family
ID=24645503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0003885A HUP0003885A2 (en) | 1996-06-06 | 1997-06-05 | Formulation for treating congestive heart failure |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0914128A1 (en) |
JP (1) | JP2000511906A (en) |
KR (1) | KR20000016406A (en) |
CN (1) | CN1226166A (en) |
AU (1) | AU3233197A (en) |
BR (1) | BR9709546A (en) |
CA (1) | CA2256720A1 (en) |
CZ (1) | CZ397698A3 (en) |
EA (1) | EA199900006A1 (en) |
HU (1) | HUP0003885A2 (en) |
IL (1) | IL126966A0 (en) |
NO (1) | NO985695L (en) |
PL (1) | PL330637A1 (en) |
TR (1) | TR199802496T2 (en) |
WO (1) | WO1997046241A1 (en) |
YU (1) | YU55998A (en) |
ZA (1) | ZA974978B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19815411A1 (en) * | 1998-04-06 | 1999-10-07 | Solvay Pharm Gmbh | Thermogenesis stimulant comprising moxonidine, useful e.g. for treating hypothermia or promoting weight loss, having no cardiac stimulant side effects |
WO2000044355A1 (en) * | 1999-01-29 | 2000-08-03 | Eli Lilly And Company | Moxonidine salts |
BR0007894A (en) * | 1999-02-01 | 2001-10-30 | Solvay Pharm Gmbh | Use of moxonidine for treatment after cardiac infarction |
ATE487712T1 (en) * | 2006-08-31 | 2010-11-15 | Chemagis Ltd | USE OF MONOXIDINE SALTS TO PURIFY MONOXIDINE |
KR100812287B1 (en) * | 2007-01-03 | 2008-03-13 | 주식회사 챠콜코리아 | Shade for a traffic signal lamp having reflective layer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
DE3617158C2 (en) * | 1986-05-22 | 1994-10-06 | Lohmann Therapie Syst Lts | Transdermal drug |
DE3729299A1 (en) * | 1987-09-02 | 1989-03-23 | Beiersdorf Ag | TRANSDERMAL THERAPEUTIC SYSTEM |
DE3904795C2 (en) * | 1989-02-17 | 2000-10-12 | Lilly Pharma Produktion Gmbh & | Pharmaceutical preparation and its use |
DE4325491A1 (en) * | 1993-07-29 | 1995-02-02 | Boehringer Ingelheim Kg | Use of centrally acting alpha-2 agonists to inhibit post-aggression metabolism |
DE4423177A1 (en) * | 1994-07-01 | 1996-01-04 | Kali Chemie Pharma Gmbh | Antihyperglycemic drugs |
CA2182851A1 (en) * | 1995-08-15 | 1997-02-16 | August Masaru Watanabe | Method for treating substance abuse withdrawal |
-
1997
- 1997-06-05 AU AU32331/97A patent/AU3233197A/en not_active Abandoned
- 1997-06-05 ZA ZA974978A patent/ZA974978B/en unknown
- 1997-06-05 WO PCT/US1997/009914 patent/WO1997046241A1/en not_active Application Discontinuation
- 1997-06-05 TR TR1998/02496T patent/TR199802496T2/en unknown
- 1997-06-05 CA CA002256720A patent/CA2256720A1/en not_active Abandoned
- 1997-06-05 BR BR9709546A patent/BR9709546A/en not_active Application Discontinuation
- 1997-06-05 IL IL12696697A patent/IL126966A0/en unknown
- 1997-06-05 HU HU0003885A patent/HUP0003885A2/en unknown
- 1997-06-05 EP EP97928011A patent/EP0914128A1/en not_active Withdrawn
- 1997-06-05 PL PL97330637A patent/PL330637A1/en unknown
- 1997-06-05 KR KR1019980709980A patent/KR20000016406A/en not_active Application Discontinuation
- 1997-06-05 JP JP10500901A patent/JP2000511906A/en active Pending
- 1997-06-05 CZ CZ983976A patent/CZ397698A3/en unknown
- 1997-06-05 CN CN97196854A patent/CN1226166A/en active Pending
-
1998
- 1998-12-04 YU YU55998A patent/YU55998A/en unknown
- 1998-12-04 NO NO985695A patent/NO985695L/en not_active Application Discontinuation
-
1999
- 1999-01-06 EA EA199900006A patent/EA199900006A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL126966A0 (en) | 1999-09-22 |
EA199900006A1 (en) | 1999-06-24 |
NO985695L (en) | 1999-02-04 |
WO1997046241A1 (en) | 1997-12-11 |
JP2000511906A (en) | 2000-09-12 |
KR20000016406A (en) | 2000-03-25 |
AU3233197A (en) | 1998-01-05 |
YU55998A (en) | 1999-11-22 |
ZA974978B (en) | 1998-12-07 |
NO985695D0 (en) | 1998-12-04 |
TR199802496T2 (en) | 1999-02-22 |
EP0914128A1 (en) | 1999-05-12 |
CZ397698A3 (en) | 1999-05-12 |
BR9709546A (en) | 1999-08-10 |
CA2256720A1 (en) | 1997-12-11 |
PL330637A1 (en) | 1999-05-24 |
CN1226166A (en) | 1999-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0102482A2 (en) | Formulations for controlling human lice | |
HUP0002196A2 (en) | Medical food for diabetics | |
IS2148B (en) | (Methylsulfonyl) phenyl-2- (5H) -furanone inhibited by COX-2 | |
DE69527509D1 (en) | HYDROGEL FORMULATION WITH CONTROLLED RELEASE | |
AU3990797A (en) | Sustained release formulation | |
ATE246919T1 (en) | IMPROVED TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TREATMENT OF PARKINSON'S DISEASE | |
CY1106763T1 (en) | PREVENTIVE OR THERAPEUTIC MEANS FOR INFLAMMATORY BOWEL DISEASES | |
ATE201597T1 (en) | ADMINISTRATION OF RILUZOLE FOR THE TREATMENT OF NEURO-AIDS | |
NO951498D0 (en) | Pharmaceutical preparation for the treatment of osteoporosis | |
UA35567C2 (en) | Pharmaceutical preparation for treating patients with coagulation impairment, method for treatment, method for pharmaceutical manufacturing | |
DK0998287T3 (en) | Use of levobupivacaine | |
DK0499923T3 (en) | Dental Adhesive | |
RU93032613A (en) | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PATIENTS WITH PROLONGED COAGULATION TIME, METHOD OF TREATING PATIENTS, USING THE EPI INHIBITOR FOR OBTAINING THE PHARMACEUTICAL PREPARATION | |
HUP0104647A2 (en) | Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient | |
NO20000446D0 (en) | Use of physiologically acceptable vanadium compounds, salts and complexes | |
DE60015508T2 (en) | C-16 UNAUDITED FP-SELECTIVE PROSTAGLANDIN ANALOGUE | |
BG106548A (en) | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog | |
HUP0003885A2 (en) | Formulation for treating congestive heart failure | |
DE59608150D1 (en) | TRANSDERMAL THERAPEUTIC SYSTEM (TTS) FOR THE ADMINISTRATION OF TESTOSTERONE | |
GB9907571D0 (en) | Compounds | |
DK0750616T3 (en) | Acid addition salts of 2,3,4,5-tetrahydro-1H-3-benzazapine compounds | |
TR199700963T1 (en) | Derivative of aminotetral for the treatment of cardiovascular diseases. | |
WO2002096870A3 (en) | Sponge-derived terpenoids and methods of use | |
BR0015781A (en) | Pharmaceutical composition for treatment of diseases associated with decreased bone mass | |
HUP0000110A2 (en) | Pharmaceutical compositions comprising azacyclic, azabicyclic or tetrahydro-pyridine-derivatives suitable for treating pain |